Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepaStem in Cirrhotic and Pre-cirrhotic NASH
NCT03963921Phase 2Completed
- Sponsor
- Cellaïon
- Start
- Apr 2019
- Primary completion
- May 2020
- Modality
- Mesenchymal Stem Cells
- Countries
- 4
01
Overview
Phase 2, open-label trial of hepastem in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Cellaïon. Primary endpoint: Incidence of Adverse Event at Day 28. Started Apr 2019; status: completed.
02
Drugs
hepastem
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03963921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03963921.